Type | Public | |
Founded | 2012 | |
Website | junshipharma.com |
CNY | |
---|---|
Revenue (Q3, 2021) | 787.5m |
Gross profit (Q3, 2021) | 316.1m |
Net income (Q3, 2021) | (401.5m) |
EBITDA (Q3, 2021) | (517.8m) |
EBIT (Q3, 2021) | (388.6m) |
Market capitalization (20-May-2022) | 75.4b |
Closing stock price (20-May-2022) | 58.0 |
Cash (30-Sept-2021) | 3.1b |
EV | 72.9b |
CNY | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Revenue | 684.0k | 766.8m | 1.5b |
Cost of goods sold | (2.0m) | (90.7m) | (372.5m) |
Gross profit | (1.3m) | 677.1m | 1.2b |
R&D expense | (538.2m) | (946.1m) | (1.8b) |
CNY | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|
Revenue | 78.5m | 226.5m | 574.9m | 1.0b | 1.6b | 311.5m | 787.5m |
Cost of goods sold | (12.7m) | (27.8m) | (90.5m) | (208.7m) | (280.5m) | (183.5m) | (286.2m) |
Gross profit | 65.8m | 199.6m | 488.5m | 797.3m | 1.3b | 313.2m | 316.1m |
R&D expense | (195.6m) | (173.2m) | (708.9m) | (1.2b) | (450.6m) | (496.6m) | (475.3m) |
CNY | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Cash | 2.8b | 1.2b | 3.4b |
Accounts Receivable | 6.6m | 163.2m | 590.3m |
Prepaid Expenses | 44.7m | 297.7m | 258.2m |
Inventories | 48.5m | 180.7m | 343.4m |
CNY | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|
Cash | 2.5b | 2.3b | 676.3m | 4.1b | 3.3b | 4.3b | 3.1b |
Accounts Receivable | 85.3m | 149.4m | 241.3m | 402.4m | 633.3m | 383.3m | 697.0m |
Prepaid Expenses | 113.7m | 164.3m | 270.1m | 269.6m | 354.7m | 405.2m | 469.3m |
Inventories | 81.3m | 111.4m | 274.5m | 329.0m | 366.9m | 414.0m | 401.4m |
CNY | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Net Income | (722.9m) | (747.7m) | (1.7b) |
Depreciation and Amortization | 32.7m | 59.8m | 119.3m |
Inventories | (19.0m) | (132.2m) | (167.0m) |
Accounts Payable | 189.9m | 86.0m | 686.0m |
CNY | Q1, 2019 | Q2, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|
Net Income | (291.2m) | 9.3m | |||||
Depreciation and Amortization | 26.6m | 100.4m | |||||
Inventories | (62.9m) | (76.5m) | |||||
Accounts Payable | 49.2m | (89.4m) |
Shanghai Junshi Biosciences revenue breakdown by business segment: 71.2% from ANTITUMOR DRUGS and 28.8% from TECHNOLOGY LICENSING INCOME
When was Shanghai Junshi Biosciences founded?
Shanghai Junshi Biosciences was founded in 2012.
Who are Shanghai Junshi Biosciences key executives?
Shanghai Junshi Biosciences's key executives are Feng Hui, Zhang Zhuobing and Yao Sheng.
How many employees does Shanghai Junshi Biosciences have?
Shanghai Junshi Biosciences has 1,875 employees.
What is Shanghai Junshi Biosciences revenue?
Latest Shanghai Junshi Biosciences annual revenue is ¥1.5 b.
What is Shanghai Junshi Biosciences revenue per employee?
Latest Shanghai Junshi Biosciences revenue per employee is ¥799.8 k.
Who are Shanghai Junshi Biosciences competitors?
Competitors of Shanghai Junshi Biosciences include ZAI Lab, Taiho Pharmaceutical and Biocon.
Receive alerts for 300+ data fields across thousands of companies